Project description
Novel peptide-based antibiotics against drug-resistant bacteria
Israel-based Omnix Medical is developing novel antibiotic agents for the treatment of infections caused by drug-resistant bacteria. The company’s proprietary platform technology is changing the biodegradability of antimicrobial peptides, creating a new class of antibiotics with a unique mechanism of action, which is effective regardless of underlying resistance patterns. The goal of the EU-funded OMN6 project is to demonstrate clinical safety and efficacy in the treatment of deadly nosocomial Acinetobacter baumannii infections. To that end, it will support Omnix Medical in the commercialisation of its lead antibiotic candidate, which has already made it past the proof-of-concept stage.
Objective
We are in living in times where the efficacy of antibiotics is no longer guaranteed. Despite the urgent need to mitigate the spread of antimicrobial resistance (AMR), very few antibiotics are being developed. AMR management costs €1.5 B and causes 33,000 deaths each year in the EU.
We at Omnix are determined to change lives and repopulate drug development pipelines by demonstrating clinical efficacy of a novel class of antibiotics. We have made potent antimicrobial peptides found in nature druggable, by hampering their biodegradability using our proprietary platform technology. The results are highly selective, life-saving therapies which are safe to humans. These bioengineered peptides constitute a new class of antibiotics due to their unique mechanism of action, which remains effective regardless of underlying resistance patterns.
We intend to solve the most urgent clinical need in infectious disease management by targeting drug resistant pathogens topping the WHO’s priority list. The project will demonstrate clinical safety and efficacy in treating A. baunmannii infections. This top-most critical pathogen exerts a mortality rate of ~40%. We have already successfully established a preclinical proof of concept for our lead candidate. Commercialisation is planned to take place with a partner from the pharma sector. The deal size is predicted to be €150-250 and conservative estimates on sales forecast revenues around €50 M five years after launch. Revenues will be reinvested into developing antibiotics for other critical pathogens and into scaling Omnix to over 150 employees.
Our approach has the potential to make a significant impact on the global AMR challenge, as we base our drug design on peptides that have remained effective for millions of years, demonstrating a low risk of trigger emergence of new resistance. Treating infections with such potent natural defenses will constitute a true paradigm shift in infections disease management.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences basic medicine medicinal chemistry
- medical and health sciences health sciences infectious diseases
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
9270401 Jerusalem
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.